Intelligent Bio Solutions announces submission of its AI response to U.S. FDA

Intelligent Bio Solutions (INBS) announced the submission of its Additional Information, AI, response to the United States Food and Drug Administration, FDA, as part of its ongoing 510(k) clearance process for planned entry to the U.S. market later this year. The response includes new positive data that strengthens the Company’s 510(k) submission and further validates the security and performance of its innovative fingerprint sweat-based drug screening technology. The Company’s updated submission incorporates data from intensive cybersecurity testing, including penetration and electromagnetic compatibility testing. These efforts have reinforced the system’s resilience across varied environments and supported targeted updates to further strengthen platform integrity and dependability.